A retrospective analysis of 148 EGFR mutant advanced NSCLC patients across 13 Swiss centers showed that 77% experienced oligoprogressive disease following treatment with first line osimertinib, a third-generation EGFR TKI, and they had a longer OS than patients who had systemic progressive disease (Schuler et al., 2024). Here, EGFR is linked to non-small cell lung carcinoma.